The 2023-2028 Outlook for Canes and Crutches in India

This study covers the latent demand outlook for canes and crutches across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the per...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Candy in India

This study covers the latent demand outlook for candy across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share th...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Candles in India

This study covers the latent demand outlook for candles across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cancer Vaccines in India

This study covers the latent demand outlook for cancer vaccines across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percen...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cancer Tumor Profiling in India

This study covers the latent demand outlook for cancer tumor profiling across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cancer Therapies in India

This study covers the latent demand outlook for cancer therapies across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the perce...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cancer Therapeutics in India

This study covers the latent demand outlook for cancer therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the pe...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cancer Testing-Screening in India

This study covers the latent demand outlook for cancer testing-screening across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, t...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cancer Supportive Care Therapeutics in India

This study covers the latent demand outlook for cancer supportive care therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cancer Supportive Care Drugs in India

This study covers the latent demand outlook for cancer supportive care drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in questio...

9/14/2022 | India Outlook 2023

This study covers the latent demand outlook for canes and crutches across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for canes and crutches. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of canes and crutches as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Cardinal Health, DeVilbiss Healthcare, Drive DeVilbiss Healthcare, Ergoactives, GF Health Products, Invacare Corporation, Medline Industries, and NOVA Medical Products. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for candy across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for candy. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of candy as including all commonly understood products falling within this broad category, such as chewing and bubble gum and all chocolate-based boxed, individual, and seasonal candies and all sugar-based candies, such as gummies, toffee, caramels, licorice, sour drops, mints, medicated throat lozenges, and lollipops, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Altoids, Arcor, August Storck, Bubble Yum, Cadburys, Cloetta, DeMet’s Candy Company, Ferrara Candy Company, Ferrero, General Mills, HARIBO of America, Hershey's, Jelly Belly Candy Company, Kellogg NA Company, LOTTE CONFECTIONARY Company, Ltd., M&M's, Mars, Meiji Holdings Company, Mondelez International, Mondeléz International, Mondelēz International, Muskoka Candy Company, Nestle, Nestlé, palmer-candy., Perfetti Van Melle, pladis global, Quality Candy Company, SUGARFINA, Inc., Sweet Candy Company., THE BANG CANDY COMPANY, and Twizzlers. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for candles across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for candles. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of candles as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Baltic Candles, Ltd., Bath & Body Works, Better Homes and Garden, Bolsius International, Bridgewater Candles, Candle Scandinavia Group AB, Ceras Roura, Circle E Candles, Colonial Candle, Contract Candles, Ltd., Delsbo Candle AB, Diptyque, Duni, Gold Canyon Candles, Hansa Candle AS, Jo Malone, KORONA Candles, Malin + Goetz, Nest, Slatkin & Company, Thymes, Village Candles, Virginia Candle / WoodWick Candles, Vollmar GmbH, White Barn Candles, and Yankee Candles. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cancer vaccines across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cancer vaccines. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cancer vaccines as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Amgen, Argos Therapeutics, Astellas Pharma, AstraZeneca, Bavarian Nordic, Bharat Biotech., Bluebird Bio, Bristol-Myers Squibb, Cytos Biotechnology, Dendreon, duro BioTech, Dynavax Technologies, Emergent BioSolutions, Galena Biopharma, Gamma Vaccines Pty, Ltd., GlaxoSmithKline, Gritstone Oncology, GSK, ImmunoBiology, Ltd., Immunomic Therapeutics, Juno Therapeutics, Juvaris Biotherapeutics, Kite Pharma, MedImmune, Merck, Merk&co, Nova Rx Corporation, Novavax, OSE Immunotherapeutics, Oxford BioMedica, PaxVax Corporation, Pfizer, Prima BioMed, Prokarium, Sanofi, Sinovac Biotech, UbiVac, Vaccinogen, Valeant Pharma, and VBI Vaccines. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cancer tumor profiling across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cancer tumor profiling. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cancer tumor profiling as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, Agendia, BD, Caris Life Sciences, Claris Lifesciences, Contextual Genomics, F. Hoffmann-La Roche, FOUNDATION Medicine, GenomeDx, Genomic Health, GenScript, Guardant Health, Helomics, Hologic, HTG Molecular Diagnostics, Illumina, Nanostring Technologies, NeoGenomics Laboratories, Oxford Gene Technology, Personal Genome Diagnostics, Perthera, Inc., Precision Medicine Group, Qiagen, Ribomed, and Siemens Healthcare. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cancer therapies across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cancer therapies. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cancer therapies as including all commonly understood products and/or services falling within this broad category, such as blood, bone, brain, breast, digestive, gastrointestinal, endocrine, eye, genitourinary, gynecologic, head and neck, respiratory, lung, and skin cancer therapies and surgery, chemotherapy, radiation, targeted, and hormonal therapy, immunotherapy, hyperthermia, and stem cell transplant treatments, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Amgen, Astellas Pharma, Astra Zeneca, Bayer, Bristol-Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Company, Eli Lilly and Company, F. Hoffmann-La Roche, Genentech, GlaxoSmithKline, GPC Biotech Ag, Johnson & Johnson, Merck, Novartis, OSI Pharmaceuticals, Pfizer, Sanofi, and Takeda Pharmaceutical Company. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cancer therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cancer therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cancer therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Amgen, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Biogen, Bristol-Meyrs Squibb Company, Bristol-Myers Squibb, Celgene Corp. (CELG), Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline plc (GSK), Johnson & Johnson, Merck & Company, Novartis, Pfizer, and Takeda Pharmaceutical Company. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cancer testing-screening across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cancer testing-screening. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cancer testing-screening as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 20/20 GeneSystems, Inc., AB SCIEX, Abcodia, Abingdon Health, and Abingdon Health, Ltd., Beckton Dickinson, Danaher, Dias Orin SPA, Epigenetics Ag, F. Hoffmann-La Roche, Genextropy, Inc., Johnson & Johnson, M Genomics, Ltd., Siemens Healthcare, and Techlab. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cancer supportive care therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cancer supportive care therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cancer supportive care therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Amgen, Bayer, Daiichi Sankyo, Heron Therapeutics, Insys Therapeutics, and Kyowa Hakko Kirin. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cancer supportive care drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cancer supportive care drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cancer supportive care drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Acacia Pharma Group, Amgen, APR, Baxter, F. Hoffmann-La Roche, Fagron, Helsinn Healthcare, Heron Therapeutics, Johnson & Johnson, Kyowa Kirin Company, Merck, Novartis, Purdue Pharma, Tesaro, and Teva Pharmaceuticals Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT